PT  - JOURNAL ARTICLE
AU  - ANGIOLO GADDUCCI
AU  - MARIA ELENA GUERRIERI
AU  - STEFANIA COSIO
AU  - MARIA GRAZIA FABRINI
AU  - CONCETTA LALISCIA
AU  - DANIELA ATTIANESE
AU  - ANNALISA ROSSI
AU  - ANNAMARIA FERRERO
TI  - Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study
DP  - 2018 Mar 01
TA  - Anticancer Research
PG  - 1695--1703
VI  - 38
IP  - 3
4099  - http://ar.iiarjournals.org/content/38/3/1695.short
4100  - http://ar.iiarjournals.org/content/38/3/1695.full
SO  - Anticancer Res2018 Mar 01; 38
AB  - Background/Aim: To assess the patterns of recurrence of node-positive endometrial cancer patients. Patients and Methods: This investigation assessed 82 patients who received different postoperative treatments. Results: Recurrence developed in 36 patients after a median time of 13.5 months, and involved the vagina, pelvic nodes, para-aortic nodes and distant sites in 5, 8, 16 and 17 patients, respectively. Five-year progression-free survival (PFS) and 5-year overall survival (OS) were 51.1% and 59.8%. PFS and OS were significantly better for endometrioid than for non-endometrioid tumors. There was a trend towards a better outcome for patients who underwent chemotherapy±radiotherapy compared to those who received radiotherapy alone. Among the former, there was a better 5-year PFS (65.8% versus 33.7%, p=0.038) in patients who received platinum/paclitaxel-based regimens compared to those who received platinum-based chemotherapy. Conclusion: Disease recurred in 43.9% of patients, and platinum/paclitaxel-based chemotherapy plus radiotherapy appeared to be the best adjuvant treatment.